MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 58 Publications

11 Customer Reviews

  • Western blot of IκBζ expression in BMDMs treated with DI and stimulated with LPS for 1 h. MG132 or bafilomycin A (BafA) were added 30 min before LPS stimulation.

    Nature, 2018, 556(7702):501-504. MG-132 purchased from Selleck.

    MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

  • HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

    HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  •  

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

    JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

  • LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

    Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NFnwbYZHfW6ldHnvckBCe3OjeR?= MUeyOUDPxE1? MV3EUXNQ M4H3OWlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN MYqyOFY6PzR7Nh?=
HL-60 MWnDfZRwfG:6aXOgRZN{[Xl? M1;5NFQxKM7:TR?= NHfsZWY1QCCq MV7EUXNQ MULJR|UxRDFyIN88US=> NFXKfJozPDZ7N{S5Oi=>
SMMC-7721 MnnPR5l1d3SxeHnjJGF{e2G7 M2frR|QxKM7:TR?= NYP2eWRNPDhiaB?= MYrEUXNQ Mmf5TWM2OD15LkGg{txO NX\CZnRYOjR4OUe0PVY>
A-549 NVHpNlkzS3m2b4TvfIlkKEG|c3H5 M1rmNVQxKM7:TR?= MkHlOFghcA>? NYjORmd{TE2VTx?= M{fVWWlEPTB:MUCg{txO NX3DZ3V5OjR4OUe0PVY>
MCF-7 MXfDfZRwfG:6aXOgRZN{[Xl? MWO0NEDPxE1? M4rmUVQ5KGh? Mon2SG1UVw>? MWXJR|UxRTdwMzFOwG0> Ml;WNlQ3QTd2OU[=
SW-480 MmXPR5l1d3SxeHnjJGF{e2G7 MkXpOFAh|ryP NIHkNG81QCCq NYriR|dHTE2VTx?= NXuwUWRUUUN3ME20JO69VQ>? MUSyOFY6PzR7Nh?=
NCI-H929 MYDDfZRwfG:6aXOgRZN{[Xl? M33MbFEh|ryP MXe3NkBp MV\EUXNQ MYTJR|UxRTBwMUeg{txO NIX2O44zPDZ{NUC4PC=>
293T M{DSUWN6fG:2b4jpZ{BCe3OjeR?= NWH4dJBnOTBizszN Mke0O|IhcA>? NXPv[4VYTE2VTx?= MWHJR|UxRDJizszN M1vTdlI1PjJ3MEi4
293T NH\ne4VHfW6ldHnvckBCe3OjeR?= NEf0c5cyOCEQvF2= MXqyOEBp MlXvSG1UVw>? MkD3UY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? M3XFclI1PjJ3MEi4
HeLa NHPDTHVMcW6jc3WgRZN{[Xl? MYGxNEDPxE1? NXfvfGZEOSCq Mmj6SG1UVw>? M4nsdWlv\HWlZYOgVGFTWCClbHXheoFo\SCkeTDpcohq[mm2aX7nJJBzd3OnYYPvcYUh[WO2aY\peJk> NHTUOnUzPDN{MUizNy=>
MDA-MB-231 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm4[IMyKM7:TR?= NHmweFc4OiCq MX7EUXNQ NIDob5JKSzVyPUCuNVgh|ryP MW[yOFE2OzJyNh?=
MCF-7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TsSVEh|ryP MWK3NkBp NITwVYtFVVOR MnzlTWM2OD1yLkGzJO69VQ>? MVuyOFE2OzJyNh?=
MCF10A M3T6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jScVEh|ryP NFPEdok4OiCq NVTaeIVqTE2VTx?= NYfYbW9EUUN3ME2wMlI6KM7:TR?= MoPHNlQyPTN{ME[=
HEK-293 M4XLZmtqdmG|ZTDBd5NigQ>? MXiyJIFv\CB{MDFOwG0> MXmyJIg> NF;vNXFFVVOR MojXTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1i MV2yN|U1ODd7MB?=
Calu6 MXjGeY5kfGmxbjDBd5NigQ>? NFOze3MyOCEQvF2= MkHmNVghcA>? MnXUSG1UVw>? MXnTbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?= MYmyN|UxPjR6Nh?=
IFN-gamma-induced RAW264.7 M4TNNGZ2dmO2aX;uJGF{e2G7 M4PzZmROW09? NIHMSYVKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5yN{eg{txO NH\qT5czOjJ5N{K3Oy=>
IPC227F NFS5cGNEgXSxdH;4bYMhSXO|YYm= NFzETYkyKM7:TR?= M3q1eVQ5KGh? NWHqUZRwTE2VTx?= NFvZUHJKSzVyPUCuNFc4KM7:TR?= MmXiNlE6OjR3Mki=
Hepa-1c1c7 NGn3b2ZHfW6ldHnvckBCe3OjeR?= M4rmRVI2KM7:TR?= M2f4XlYhcA>? M4P6cGROW09? NETKR5JKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVt NGLxXG4zODN7MkW0OC=>
COS-7 NGW2TYdEgXSxdH;4bYMhSXO|YYm= MmrDNVAh|ryP NYLsNW1{TE2VTx?= M4HtRWlEPTB:MUCg{txO NVXUOGg2OThyOEiwPVc>
HuH-7 NGn3dZdEgXSxdH;4bYMhSXO|YYm= MWSxNEDPxE1? M3PVSGROW09? M{[4PGlEPTB:MUCg{txO NILnb5YyQDB6OEC5Oy=>
OCI-Ly3 NHLMVGlHfW6ldHnvckBCe3OjeR?= M{jIPVExKM7:TdMg MnS0OEBp MkfCSG1UVw>? MWnJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>? NWX4NJdjOThyMkSxNVM>
A2780 cDDP MWfBdI9xfG:|aYOgRZN{[Xl? NFnkZZkzPCCq NWXWOnJDTE2VTx?= M{jX[Glv\HWlZYOgZZBweHSxc3nzJIJ6KGmwaHnibZRqdmdiUGTFUkBl\We{YXTheIlwdg>? MYqxO|Y5PDBzOB?=
LPS-stimulated RAW264.7 cells NX7RdFdwTnWwY4Tpc44hSXO|YYm= NH3ke4FFVVOR Moi2TY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o M2nyXlE4PDB5Mke3
PC12 M{PRSGZ2dmO2aX;uJGF{e2G7 NWTQ[nFqOTByIN88UeKh M4LPVVI1KGh? MX3EUXNQ M32x[mlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NYjpc4diOTdzNUi0OVQ>
PC3 M3TCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS4e|YzOCEQvF2= MXm0PEBp NX;wRlNzTE2VTx?= MlrDTWM2OD1yLk[g{txO NXHGeFZ3OTZ4OE[1N|c>
LP-1 MWLBdI9xfG:|aYOgRZN{[Xl? NIfzW5c{ODBibl2= NXvIO2RlOjRiaB?= NHj2[mZFVVOR Mkn5TY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw> NYfuXHBIOTV7NUi1PFk>
ES6 NYTaOIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX2dG1ZUUN3ME2wMlAyOzB4IN88US=> Ml\JV2FPT0WU
A101D MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHMN3lZUUN3ME2wMlA{Ojd7IN88US=> MmXUV2FPT0WU
OCUB-M NX;aeYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GyUGlEPTB;MD6wN|c{PyEQvF2= M{Hqb3NCVkeHUh?=
LB2518-MEL NGLuVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL1VnJHUUN3ME2wMlA{PzZizszN NHH0Z3hUSU6JRWK=
SH-4 NF3Ld|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkizTWM2OD1yLkC0N|Eh|ryP NIXidplUSU6JRWK=
KNS-42 M1vUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\LclZKSzVyPUCuNFQ1PDFizszN MoHhV2FPT0WU
DSH1 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEWyPFkh|ryP M33GTnNCVkeHUh?=
NTERA-S-cl-D1 NELv[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjVXlJFUUN3ME2wMlA2Pzd{IN88US=> Mkn6V2FPT0WU
D-542MG NFXkdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vVOWlEPTB;MD6wOVk2PyEQvF2= NVXIUpc5W0GQR1XS
KS-1 NV3hb|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXMXWhKSzVyPUCuNFY1PThizszN MmfRV2FPT0WU
BL-41 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jSUmlEPTB;MD6wOlk1PyEQvF2= MlzYV2FPT0WU
LXF-289 NWXwdJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXmcGFmUUN3ME2wMlA4ODZ4IN88US=> M3;ITnNCVkeHUh?=
D-247MG M1PKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P2[2lEPTB;MD6wO|IxQSEQvF2= NWHS[FNCW0GQR1XS
MMAC-SF M2nZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEeyOlgh|ryP NYHpZpVmW0GQR1XS
CP66-MEL NWHSenIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEe1JO69VQ>? M3\qVXNCVkeHUh?=
LB771-HNC NXP4Nnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq1TWM2OD1yLkC4NFM3KM7:TR?= NH[5[|hUSU6JRWK=
no-10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEi5NFkh|ryP MkjPV2FPT0WU
A388 M{\qR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEmwOlUh|ryP MXfTRW5ITVJ?
OPM-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hTWM2OD1yLkGwOFc1KM7:TR?= NXjOZlU5W0GQR1XS
OVCAR-4 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMUC5N|gh|ryP MonNV2FPT0WU
HOP-62 NHfYPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMUC5OFkh|ryP NX7FNmd3W0GQR1XS
ML-2 NUnRfFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PTT2lEPTB;MD6xNVgxPiEQvF2= NFXFenBUSU6JRWK=
UACC-257 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jsZWlEPTB;MD6xNVkzPyEQvF2= NFnTd3VUSU6JRWK=
NEC8 NW\I[5JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDIOFNKSzVyPUCuNVE6QTVizszN NXPRN2FkW0GQR1XS
ONS-76 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfXbXhRUUN3ME2wMlEzQTN3IN88US=> M4m4T3NCVkeHUh?=
KE-37 NU\sUZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHKTWM2OD1yLkGzNlc5KM7:TR?= NGDlXFRUSU6JRWK=
HT-144 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnLTWM2OD1yLkGzPFk2KM7:TR?= M2DWTXNCVkeHUh?=
LB2241-RCC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rRNGlEPTB;MD6xOFI1PyEQvF2= NH;5SIlUSU6JRWK=
TE-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS5TWM2OD1yLkG0Nlc5KM7:TR?= MkTMV2FPT0WU
KINGS-1 M4\ndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TEeGlEPTB;MD6xOFc6KM7:TR?= NYn3SoRMW0GQR1XS
NCI-H69 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMUWxOFEh|ryP MkXTV2FPT0WU
CAS-1 NV3L[YJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3vdlV7UUN3ME2wMlE2PDh{IN88US=> MVHTRW5ITVJ?
D-263MG NIHLNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXpcIJyUUN3ME2wMlE3ODB4IN88US=> Ml\GV2FPT0WU
A253 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3iTWM2OD1yLkG2NVI5KM7:TR?= M{\0VnNCVkeHUh?=
PF-382 NXX5[IwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMU[3NFYh|ryP NHXPV5ZUSU6JRWK=
CESS NYDkNnFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0UWlEPTB;MD6xO|A3KM7:TR?= NVjhVYlwW0GQR1XS
MZ2-MEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD1yLkG3OVU6KM7:TR?= NH;GcZdUSU6JRWK=
HEL Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUi1NVch|ryP NVG3bGo2W0GQR1XS
D-392MG NUfsWldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\Tb2lEPTB;MD6xPVEyPSEQvF2= MXTTRW5ITVJ?
SK-LMS-1 M{Lud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q0RWlEPTB;MD6xPVMxOyEQvF2= MlLrV2FPT0WU
GI-ME-N M4jhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjIPGZEUUN3ME2wMlE6OzB4IN88US=> NVPtSJg4W0GQR1XS
LB831-BLC MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMUmzOEDPxE1? M2DRNHNCVkeHUh?=
DU-4475 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXflSXZuUUN3ME2wMlE6PjV6IN88US=> M{K0dHNCVkeHUh?=
IST-SL1 NYTYW2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrYfVBKSzVyPUCuNlAxQTRizszN MlXYV2FPT0WU
GAK M{fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG5TWM2OD1yLkKwOVM1KM7:TR?= NYqxZ3VWW0GQR1XS
EW-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LTWM2OD1yLkKxNFQ4KM7:TR?= Ml7RV2FPT0WU
LAMA-84 NV36UYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP5NlZDUUN3ME2wMlIyQDVzIN88US=> NUPrdnpMW0GQR1XS
SK-UT-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74O3hKSzVyPUCuNlIxPDlizszN MVPTRW5ITVJ?
VA-ES-BJ NEi2cJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluzTWM2OD1yLkKyNlU4KM7:TR?= NW\RSoMzW0GQR1XS
ACN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMkK2N|gh|ryP MY\TRW5ITVJ?
SK-PN-DW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMkOxPUDPxE1? MonEV2FPT0WU
HD-MY-Z NULLTFFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMkOzNFMh|ryP M{C4THNCVkeHUh?=
LB373-MEL-D MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPwcHhKSzVyPUCuNlQyQThizszN MlXEV2FPT0WU
COLO-829 NVPIcYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLoTWM2OD1yLkK0NlU4KM7:TR?= M2GydXNCVkeHUh?=
ES8 NW\jTmd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMkS3OlMh|ryP M13nOHNCVkeHUh?=
RXF393 NIfJdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XGUWlEPTB;MD6yOVAyPSEQvF2= MmHwV2FPT0WU
TK10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrieHlIUUN3ME2wMlI2PDN3IN88US=> Ml:yV2FPT0WU
LOUCY NV[5d|h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrWOoNKSzVyPUCuNlU1PTZizszN MUXTRW5ITVJ?
MZ7-mel MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLKZ2xMUUN3ME2wMlI3Ozd2IN88US=> NXrDSY9PW0GQR1XS
CP67-MEL M4G0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETTSFZKSzVyPUCuNlY4OyEQvF2= Moi3V2FPT0WU
C2BBe1 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofUTWM2OD1yLkK3PVA4KM7:TR?= MUfTRW5ITVJ?
K052 M1;MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMki5PUDPxE1? M1\xdXNCVkeHUh?=
MOLT-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPYcm9KSzVyPUCuNlk2OjRizszN NFu3bWlUSU6JRWK=
KNS-81-FD NWLzT3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPGTWM2OD1yLkOwN|I{KM7:TR?= NFfZNWxUSU6JRWK=
CMK NFK1UWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnIeJROUUN3ME2wMlMyOTJizszN NWLT[XN5W0GQR1XS
LAN-6 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTrWW9QUUN3ME2wMlMyOyEQvF2= NF7PRVBUSU6JRWK=
KLE NF76ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnDTWM2OD1yLkOxN|A3KM7:TR?= NELp[opUSU6JRWK=
NCCIT MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq0WYkyUUN3ME2wMlMyPzh|IN88US=> MoPqV2FPT0WU
HH MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7tTWM2OD1yLkOyPFk4KM7:TR?= NYHvN2c6W0GQR1XS
TE-8 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW1[ZlKSzVyPUCuN|QzPzlizszN M{CycXNCVkeHUh?=
GDM-1 NHy0XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r5fGlEPTB;MD6zOVExPCEQvF2= MYLTRW5ITVJ?
NCI-H747 NGPoOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorVTWM2OD1yLkO3NVA{KM7:TR?= NYPHRVBLW0GQR1XS
NCI-H1092 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwM{i4OFQh|ryP NIHl[mhUSU6JRWK=
8-MG-BA NXTyWGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e2eWlEPTB;MD6zPVg{PyEQvF2= MY\TRW5ITVJ?
NB17 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNEK5O{DPxE1? NFe4TW5USU6JRWK=
LC4-1 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTjRYd2UUN3ME2wMlQ{PjB5IN88US=> NXvQRXBtW0GQR1XS
TE-1 M3vtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzF[YhFUUN3ME2wMlQ2OTF7IN88US=> MoXxV2FPT0WU
KALS-1 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LpUWlEPTB;MD60OlU5PCEQvF2= MmjTV2FPT0WU
CCRF-CEM Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjMcVBCUUN3ME2wMlQ4Pjd2IN88US=> Ml3jV2FPT0WU
OS-RC-2 MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ZSnJqUUN3ME2wMlQ4QTd{IN88US=> NELJeGdUSU6JRWK=
A704 M{TtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;qdHBZUUN3ME2wMlQ5Pjl{IN88US=> MlTnV2FPT0WU
BB49-HNC MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL2bJBKSzVyPUCuOFkxQTZizszN NV\ZZ|A{W0GQR1XS
EVSA-T NWrR[XN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7MVldKSzVyPUCuOFk6OTFizszN M3fUVHNCVkeHUh?=
Mo-T NYPsVIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPuXI5KSzVyPUCuOVE4PjJizszN MYjTRW5ITVJ?
MONO-MAC-6 M1r5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrER4xJUUN3ME2wMlU{PjFzIN88US=> M4CwV3NCVkeHUh?=
BB65-RCC MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rkVGlEPTB;MD61OlgyOSEQvF2= NUP1OplLW0GQR1XS
NCI-H1882 M1PyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzCTWM2OD1yLkW5NFM3KM7:TR?= MVvTRW5ITVJ?
TE-9 NXTLTYdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCS2lEPTB;MD62NVA{OyEQvF2= NGGxVFVUSU6JRWK=
NCI-H2126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jq[GlEPTB;MD62NlY3QSEQvF2= M4nCUHNCVkeHUh?=
SF268 NIfseYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7wTWM2OD1yLk[1OlQyKM7:TR?= MWDTRW5ITVJ?
SW872 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:2N5RKSzVyPUCuOlU4OjlizszN NFnze3RUSU6JRWK=
LS-513 NHTIc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[3Z|ZKSzVyPUCuOlY4PTFizszN NFPYRmJUSU6JRWK=
NCI-H1355 NFq0U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwNki2NVkh|ryP NEftcoNUSU6JRWK=
BL-70 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNkmzPFgh|ryP NYLITmk3W0GQR1XS
NCI-SNU-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDseXlKSzVyPUCuOlk2PDVizszN M1HhdXNCVkeHUh?=
SNU-C2B M{noeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjWTWpwUUN3ME2wMlcxPzN7IN88US=> NU\Qd3pmW0GQR1XS
GB-1 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrOTWM2OD1yLkeyNVI1KM7:TR?= NWDTfYV4W0GQR1XS
CTB-1 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXifZJJUUN3ME2wMlc4QTV3IN88US=> M4LHdHNCVkeHUh?=
Becker NVr1dpV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILQfoVKSzVyPUCuO|k3OjFizszN NXLIcYg3W0GQR1XS
KM12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDQdGJHUUN3ME2wMlg2PDZ4IN88US=> M{ntW3NCVkeHUh?=
ES7 M1XzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrDcmNKSzVyPUCuPFk3PSEQvF2= NVqzOJBuW0GQR1XS
COLO-684 M1LWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvETWM2OD1yLkmwOlU5KM7:TR?= MnfsV2FPT0WU
HCC2998 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHSTWM2OD1yLkmzPFU1KM7:TR?= MWfTRW5ITVJ?
TE-10 M{\aZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwOU[0N{DPxE1? NHfhe4NUSU6JRWK=
SF126 M3PwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTrTWM2OD1yLkm4PVcyKM7:TR?= M4LUXHNCVkeHUh?=
EKVX M{Hwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPkOmRSUUN3ME2xMlA{PDR{IN88US=> Ml2wV2FPT0WU
KARPAS-45 MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[4ZmlEPTB;MT6wOFAyPiEQvF2= MV;TRW5ITVJ?
KGN NUHMdpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwMEWwOFUh|ryP Mn3EV2FPT0WU
ES1 NYXPVmZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwMEe5NlEh|ryP NULEbnVZW0GQR1XS
L-540 NX;zNJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInxTpFKSzVyPUGuNVE5OzlizszN NX;YcWJuW0GQR1XS
KURAMOCHI M3jaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH3UWdKUUN3ME2xMlEzOzd2IN88US=> MmHiV2FPT0WU
LU-65 NGjRO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljyTWM2OD1zLkGyO|U{KM7:TR?= NVjVU3FrW0GQR1XS
MFH-ino NWHYeIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK5SWlKSzVyPUGuNVc2ODFizszN Mnf3V2FPT0WU
NCI-H23 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnnTWM2OD1zLkKwOFEh|ryP M1i4W3NCVkeHUh?=
IA-LM M2W1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3te3pKSzVyPUGuNlQyOTZizszN MYDTRW5ITVJ?
PSN1 NIjrOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLMTWM2OD1zLkK3NFE3KM7:TR?= Mn\jV2FPT0WU
NCI-H719 NHXCN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwMke0NVEh|ryP MYDTRW5ITVJ?
SW684 M1nFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjjPGxKSzVyPUGuNlg3PTlizszN NUn0XWxDW0GQR1XS
HCE-4 M3jX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwM{CyNlEh|ryP Mm\CV2FPT0WU
EW-16 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\VTWM2OD1zLkOxN|Q4KM7:TR?= M3PhS3NCVkeHUh?=
NCI-H128 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwM{W4NVQh|ryP NYKyNG55W0GQR1XS
HC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXyc5NnUUN3ME2xMlM5OTdizszN M{jzcnNCVkeHUh?=
IST-MES1 NIDDbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwNECyNFgh|ryP NF3kW2RUSU6JRWK=
Raji MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r5SmlEPTB;MT60NVg2KM7:TR?= MUnTRW5ITVJ?
DMS-114 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrnTVh1UUN3ME2xMlQ1PTN7IN88US=> NW[1OI5iW0GQR1XS
GI-1 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli1TWM2OD1zLkS3NVMyKM7:TR?= MYjTRW5ITVJ?
NCI-H2081 NVnoUHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HGN2lEPTB;MT61OVE6PiEQvF2= NUXLPXpyW0GQR1XS
LC-1F NG\FdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDOcXNOUUN3ME2xMlU2OTl6IN88US=> M4TMWXNCVkeHUh?=
NCI-H2227 NGS4b|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\wUVNCUUN3ME2xMlYyPTZzIN88US=> NVf2eFFvW0GQR1XS
D-502MG NWrxb|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XBOGlEPTB;MT62O|IyOSEQvF2= M1PGenNCVkeHUh?=
NCI-H2141 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;HXoVKSzVyPUGuOlc{OTdizszN M2P4NnNCVkeHUh?=
LS-411N Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWemlEPTB;MT62PVgxPyEQvF2= MljyV2FPT0WU
SU-DHL-1 NWnISohIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFwN{GyPFEh|ryP MknsV2FPT0WU
BB30-HNC MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPPTWM2OD1zLkeyOlg2KM7:TR?= NInPd3pUSU6JRWK=
TE-15 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET0W2lKSzVyPUGuPVI{PzNizszN MWjTRW5ITVJ?
JVM-3 NWHzd5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SxdGlEPTB;MT65N|kxPCEQvF2= M2\lTHNCVkeHUh?=
IST-SL2 NV65PYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOzcJhKSzVyPUKuNFEzPTJizszN NXj4SmJGW0GQR1XS
EW-18 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HTdGlEPTB;Mj6wNlM{PyEQvF2= M163c3NCVkeHUh?=
DJM-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37XSmlEPTB;Mj6wNlU2OiEQvF2= NIjO[YZUSU6JRWK=
no-11 M2TteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXycIVKUUN3ME2yMlA{OTB2IN88US=> NHraUm1USU6JRWK=
QIMR-WIL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm5[VNKSzVyPUKuNVY4PjJizszN MmLsV2FPT0WU
MC-CAR NFHxNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSyTWM2OD1{LkKyPVUh|ryP MmTYV2FPT0WU
KM-H2 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwMkmwOFMh|ryP MmX6V2FPT0WU
ECC12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwM{e5OEDPxE1? NEmwbVBUSU6JRWK=
HCE-T NGTlO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwNES4PFMh|ryP M37qWXNCVkeHUh?=
MFM-223 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwNUC4O|Eh|ryP NHn5e|hUSU6JRWK=
SW982 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PLdWlEPTB;Mj61NVQ5KM7:TR?= MXfTRW5ITVJ?
KG-1 M3nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHmfYF2UUN3ME2yMlg5PzlzIN88US=> NEi5VGtUSU6JRWK=
ES4 M364d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHnUmoxUUN3ME2zMlA3OTFzIN88US=> MXTTRW5ITVJ?
SCC-3 NYroSnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNwMUC4OFgh|ryP MV3TRW5ITVJ?
RH-1 NIn5cFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\BTWM2OD1|LkO4O|Q5KM7:TR?= NGPFU|dUSU6JRWK=
NCI-H748 NX\aTmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnyR4tKSzVyPUOuOFQzPjZizszN MYLTRW5ITVJ?
HCC2218 NX3kdlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwNE[5N|ch|ryP MXfTRW5ITVJ?
MEG-01 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK2UGFKSzVyPUOuOVk3QCEQvF2= MmnXV2FPT0WU
NB12 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32zT2lEPTB;Mz61PVg5QCEQvF2= NXu4W|M2W0GQR1XS
SNB75 NVHTe|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwNkCxNFMh|ryP MoKzV2FPT0WU
KMS-12-PE M4HITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTNwNke3NlMh|ryP NH;KVIlUSU6JRWK=
SKM-1 M{XDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\oPFJLUUN3ME2zMlcyOzd4IN88US=> M{XOenNCVkeHUh?=
COLO-320-HSR MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHjWFVKSzVyPUOuO|U3OzRizszN NHH1T3BUSU6JRWK=
NKM-1 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnxfWZWUUN3ME2zMlc4Ozd6IN88US=> MlTYV2FPT0WU
TE-6 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwOUS1OlEh|ryP NIjSRXRUSU6JRWK=
D-336MG NHfITpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXzbYNKSzVyPUSuNFEyPjZizszN MnOwV2FPT0WU
NCI-H1650 NIXXWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LIZWlEPTB;ND6xOVc6PyEQvF2= Mo\yV2FPT0WU
ES3 NWPERmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fvdGlEPTB;ND6zNlgzPCEQvF2= NX;GcpNsW0GQR1XS
YT M3rMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC4ZYVKSzVyPUSuN|U1OjRizszN NE\t[ZBUSU6JRWK=
ES5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnToTWM2OD12LkSwNlU2KM7:TR?= M2PIPXNCVkeHUh?=
LB647-SCLC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G1SGlEPTB;ND61OlMxQCEQvF2= MlHRV2FPT0WU
HAL-01 NWf5VnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\OWVVKSzVyPUSuOVcxOzRizszN MVPTRW5ITVJ?
LP-1 NYG0TpljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnZdFBKSzVyPUSuO|I{PzFizszN Ml:0V2FPT0WU
BC-1 M321OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwMEC0OFch|ryP MXnTRW5ITVJ?
EB-3 NXfmfFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK0TWM2OD13LkCzNFQyKM7:TR?= MYPTRW5ITVJ?
GT3TKB NIn0V|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDTWM2OD13LkG3OlYzKM7:TR?= NXrXV5EzW0GQR1XS
NCI-H209 NH7hNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTVwMUmzOVIh|ryP M1\FOnNCVkeHUh?=
BT-474 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXyOGpKSzVyPUWuNlMyODJizszN NIPOTHhUSU6JRWK=
RKO NIDxZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jibWlEPTB;NT6yN|QzOiEQvF2= MmXTV2FPT0WU
SIMA MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn5OHNoUUN3ME21MlMxPzZ3IN88US=> M4nkS3NCVkeHUh?=
RL M1nFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HxfGlEPTB;NT6zO|U1OSEQvF2= MULTRW5ITVJ?
GCIY MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTVwNEeyN|Yh|ryP MXTTRW5ITVJ?
Calu-6 NH;oVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTVwNkKyJO69VQ>? M{jqVnNCVkeHUh?=
ALL-PO NXOzV4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwNkO3PVUh|ryP NUO0RpZCW0GQR1XS
ARH-77 NVjRe|BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHBZodLUUN3ME21MlY4ODh5IN88US=> NV3hc2JtW0GQR1XS
A4-Fuk NHfxeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPHTWM2OD14LkC4NVE5KM7:TR?= M1ziO3NCVkeHUh?=
NCI-H1581 M2XMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\YPXVnUUN3ME22MlI{QDR7IN88US=> M2rNT3NCVkeHUh?=
HUTU-80 NHfvc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PyeGlEPTB;Nj6zOlg6PyEQvF2= NVu3TWdCW0GQR1XS
TGW NYrZXmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPqOpVKUUN3ME22MlQ2PTl|IN88US=> NYTFW|RVW0GQR1XS
SK-N-FI NX6xR3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHZPGZGUUN3ME22MlQ2QDV2IN88US=> Mm\BV2FPT0WU
U-266 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq0TWM2OD14LkWxPVI3KM7:TR?= MkfIV2FPT0WU
EM-2 NXjPcWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjjb4s6UUN3ME22MlY4ODl7IN88US=> NFfjTXZUSU6JRWK=
NMC-G1 NHPXUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;LNmlEPTB;Nj63NVg6PSEQvF2= MmO5V2FPT0WU
KASUMI-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwOES3PFch|ryP MUPTRW5ITVJ?
NALM-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\DW2FKSzVyPU[uPFY4PTRizszN NIrQRZNUSU6JRWK=
OCI-AML2 M3Hte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKyTWM2OD15LkCwN|I3KM7:TR?= MWDTRW5ITVJ?
SHP-77 NVnGOmpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWwO|RKSzVyPUeuNlI1OyEQvF2= NV3U[GlUW0GQR1XS
NOMO-1 NVjnXYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTrWXRSUUN3ME23MlI1OjV2IN88US=> M3\PXnNCVkeHUh?=
SK-N-DZ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\FO2p2UUN3ME23MlcyODh7IN88US=> MlLlV2FPT0WU
LB1047-RCC NUixPG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3KTWM2OD15LkeyNlMyKM7:TR?= M2DIdHNCVkeHUh?=
MZ1-PC M2ToNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjYOnVnUUN3ME23Mlg3PTV6IN88US=> NYi5OZdyW0GQR1XS
NB10 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTdwOUm1OVYh|ryP M3Hz[HNCVkeHUh?=
RL95-2 NF;DRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mSm5wUUN3ME24MlExQDR{IN88US=> M4\lZ3NCVkeHUh?=
OMC-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTMTWM2OD16LkWyNVkyKM7:TR?= MXfTRW5ITVJ?
D-283MED MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHD[HdKSzVyPUiuPVE4OTlizszN M2LtVnNCVkeHUh?=
MC116 M2G5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPFUHpSUUN3ME24Mlk4QTRizszN MnjYV2FPT0WU
SJSA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLITWM2OD17LkC5NFkyKM7:TR?= NVXxcmtlW0GQR1XS
JiyoyeP-2003 M1zqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\zVmlEPTB;OT6yPVMyPyEQvF2= NIixNldUSU6JRWK=
IST-MEL1 NFXxOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[3[JAzUUN3ME25Mlc1OTl6IN88US=> NV6yT4hXW0GQR1XS
CTV-1 NFjzWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG4TWxrUUN3ME2xNE4xQTd7IN88US=> MXrTRW5ITVJ?
NH-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;HTWM2OD1zMD6yOFM{KM7:TR?= MVLTRW5ITVJ?
CA46 NVz5XplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj5[5lSUUN3ME2xNE4{PjFizszN NHvwW3dUSU6JRWK=
NCI-SNU-1 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq1c|hrUUN3ME2xNE41QTZ7IN88US=> MWTTRW5ITVJ?
SCLC-21H M3v1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjudZZvUUN3ME2xNE43PTl4IN88US=> NFLMRWFUSU6JRWK=
EC-GI-10 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPKSnNnUUN3ME2xNE44ODNzIN88US=> NUjjXI8yW0GQR1XS
SR MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hr[WlEPTB;MUGuNFE5PSEQvF2= M{\tbXNCVkeHUh?=
NCI-H1648 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fMd2lEPTB;MUGuNFk3PSEQvF2= NV;Pc492W0GQR1XS
TGBC1TKB NFLWRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K5RmlEPTB;MUGuOFExOiEQvF2= NHzteJRUSU6JRWK=
EW-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHOTWM2OD1zMT61NVg3KM7:TR?= MYTTRW5ITVJ?
SK-MM-2 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzLkiwOlEh|ryP MnLaV2FPT0WU
NCI-H524 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTJTWM2OD1zMT65PFIzKM7:TR?= MkjXV2FPT0WU
NOS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DmbGlEPTB;MUKuNFM1PSEQvF2= MlvTV2FPT0WU
AM-38 NFr0dWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF{LkW2N|Mh|ryP NHy3T4lUSU6JRWK=
A498 NV;0O|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX4cWI6UUN3ME2xNk44ODZ7IN88US=> MYjTRW5ITVJ?
KARPAS-422 M3vYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXsTWM2OD1zMj63OFk3KM7:TR?= M{XneXNCVkeHUh?=
LU-139 NHTteJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF{LkmwNlYh|ryP NWSxUZc4W0GQR1XS
COR-L88 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrSTWM2OD1zMj65N|gzKM7:TR?= M{K3T3NCVkeHUh?=
K5 M3zORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj5TWM2OD1zMj65OFYzKM7:TR?= M1y1cHNCVkeHUh?=
NB13 NHrVUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jVV2lEPTB;MUKuPVc5OyEQvF2= MnPtV2FPT0WU
MRK-nu-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF|LkG5OUDPxE1? M1TvXHNCVkeHUh?=
MHH-NB-11 NVjRfolYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml61TWM2OD1zMz6yPVAzKM7:TR?= NWHkWG05W0GQR1XS
KU812 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7nO3lKSzVyPUGzMlYyOjRizszN NHTKeJZUSU6JRWK=
TE-12 NGDPeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnJ[lVyUUN3ME2xN{43QTl2IN88US=> Mlq2V2FPT0WU
NCI-N87 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTuZ2oxUUN3ME2xN{44OzZizszN Mn7xV2FPT0WU
EB2 NWi5bHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYO2lEPTB;MUOuPFUxPSEQvF2= NGOxTZBUSU6JRWK=
DB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF|Lkm4PFUh|ryP MV\TRW5ITVJ?
697 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT6d45KSzVyPUG0MlQ2OTFizszN MXXTRW5ITVJ?
MSTO-211H NU\h[3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGyTWM2OD1zND63OFQ5KM7:TR?= MlPMV2FPT0WU
JVM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnp[m9KSzVyPUG0Mlc4OzVizszN M{LVNXNCVkeHUh?=
COLO-824 NXTlfGlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ThTWlEPTB;MUSuO|k6PCEQvF2= MYDTRW5ITVJ?
BC-3 M2X4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkO5PEDPxE1? NFTQ[IJUSU6JRWK=
BOKU M4\WOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTuVHVKSzVyPUG1Mlk3ODhizszN NH;Db2tUSU6JRWK=
GOTO NIHOfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L3U2lEPTB;MU[uPVYyPyEQvF2= Mnj1V2FPT0WU
HCC2157 M3Ha[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzkTWM2OD1zNz60O|U2KM7:TR?= MorOV2FPT0WU
LS-1034 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF5Lk[4NVgh|ryP MWjTRW5ITVJ?
CAL-148 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF5Lkm3PVYh|ryP MX7TRW5ITVJ?
MOLT-4 NH\FboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF74epBKSzVyPUG4MlgzODhizszN NH;DSlJUSU6JRWK=
Daudi MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITMb4pKSzVyPUG4MlkzOzFizszN MkjuV2FPT0WU
J-RT3-T3-5 NGnyOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHnTHdKSzVyPUG5MlQxPjZizszN Mn;iV2FPT0WU
KMOE-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\oPJRKSzVyPUG5MlY1QDJizszN MWDTRW5ITVJ?
HL-60 M37hd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPzZ4htUUN3ME2yNE4yQTZ3IN88US=> M2jxUHNCVkeHUh?=
P31-FUJ M2fKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnlNFJ6UUN3ME2yNE41PzV|IN88US=> NXKzPZlMW0GQR1XS
IM-9 NI[xcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCwT3E{UUN3ME2yNE43OjJ2IN88US=> Mk\lV2FPT0WU
HDLM-2 NHnTdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm3W41UUUN3ME2yNE45QDJzIN88US=> MXPTRW5ITVJ?
NCI-H1304 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHrTWM2OD1{MT6wN|EyKM7:TR?= M4Dyd3NCVkeHUh?=
NCI-H345 NHvBRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17wW2lEPTB;MkGuNFY1OyEQvF2= Mn;vV2FPT0WU
RPMI-6666 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\xO2lEPTB;MkGuN|YxOiEQvF2= NGjt[|lUSU6JRWK=
GR-ST Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\tUpFKSzVyPUKxMlQyPyEQvF2= MoHCV2FPT0WU
CHP-126 NGLkcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1uxVmlEPTB;MkGuOlE5OSEQvF2= Mn;NV2FPT0WU
EHEB NXjUXGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJzLk[3N|Eh|ryP M1LSRXNCVkeHUh?=
CPC-N NXniVo5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfzfmJJUUN3ME2yOE4xOjBzIN88US=> MnHFV2FPT0WU
NB1 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ2Lk[5N|kh|ryP NX;jXodwW0GQR1XS
LS-123 NFHjbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvvV4tKSzVyPUK0MlkxOTJizszN NGKxXIdUSU6JRWK=
ST486 M1rJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\wbGlEPTB;MkWuNVEyOyEQvF2= M{HlXHNCVkeHUh?=
NCI-H1963 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvxO2FKSzVyPUK2MlA3OjNizszN MnrDV2FPT0WU
U-87-MG MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrXeVVKSzVyPUK2Mlc3PDRizszN NYHpSYdCW0GQR1XS
COR-L279 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJ4Lke5NlIh|ryP MoPBV2FPT0WU
LU-165 M1\kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrl[mxKSzVyPUK4MlA5PjFizszN M2nHWHNCVkeHUh?=
COLO-800 NGKxc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLyNHdKSzVyPUK4MlI6PTZizszN Mmr3V2FPT0WU
ETK-1 NIPEWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrDXlZKSzVyPUK4MlM1PDZizszN Ml;mV2FPT0WU
LNCaP-Clone-FGC NGr0fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ7LkmyPFEh|ryP MmKzV2FPT0WU
SIG-M5 NX\lSmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP5Wm9KSzVyPUOwMlc6PTJizszN MnvtV2FPT0WU
NB6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTYTWM2OD1|MD65OVA{KM7:TR?= NFvieIxUSU6JRWK=
NCI-H2107 M1nUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHwfW1KSzVyPUOxMlI{OzhizszN MY\TRW5ITVJ?
SNU-C1 NIH5WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPaSZBKSzVyPUOxMlMyOjZizszN MW\TRW5ITVJ?
JAR MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLQNIE{UUN3ME2zNU4{Pzl7IN88US=> MnLIV2FPT0WU
L-363 NV\Hd|RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXCTWM2OD1|Mj6yNVQ1KM7:TR?= Ml;sV2FPT0WU
EW-24 M3vHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN{LkO0O|Qh|ryP MV\TRW5ITVJ?
NB69 M1XyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nCUGlEPTB;M{OuOlQ2PCEQvF2= M4DqWHNCVkeHUh?=
EW-13 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN|Lki5Olkh|ryP MVXTRW5ITVJ?
Ramos-2G6-4C10 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjUcJpKSzVyPUO0MlI6QTNizszN NGLVbmVUSU6JRWK=
TE-11 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN2LkS4NlIh|ryP NW[4e49xW0GQR1XS
L-428 NFLJcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjnfXdKSzVyPUO0Mlc2OzZizszN M3X5UHNCVkeHUh?=
KP-N-YN NVraXI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLZeVVKSzVyPUO0MlkxPTdizszN NHnLNYVUSU6JRWK=
CGTH-W-1 NYLQN2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN4LkmwOFgh|ryP MWXTRW5ITVJ?
K-562 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XNUWlEPTB;M{euNFg3PCEQvF2= MnTtV2FPT0WU
NCI-H1299 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXQNYVZUUN3ME2zPE4yPjB|IN88US=> MUDTRW5ITVJ?
RCC10RGB NWDlWHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTpZYRyUUN3ME2zPE4zODh|IN88US=> M3fKfnNCVkeHUh?=
NCI-SNU-16 NUjSfZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzBTWM2OD1|OD61OlU{KM7:TR?= NEHYU5dUSU6JRWK=
LC-2-ad NIKxU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN7LkSzN|ch|ryP M33GRnNCVkeHUh?=
MHH-PREB-1 M{\rPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzHTWM2OD1|OT63N|g5KM7:TR?= MXzTRW5ITVJ?
NCI-H64 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq1U2dFUUN3ME20NE4xQTR6IN88US=> MUjTRW5ITVJ?
LB996-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLOWolKSzVyPUSwMlg4OTZizszN NXX6cJJCW0GQR1XS
DEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjweYlqUUN3ME20NU41PDB3IN88US=> MnrNV2FPT0WU
MLMA NHvZdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnR[FJKSzVyPUSxMlc2QTVizszN M3fIPHNCVkeHUh?=
SBC-1 M2TlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjRTWM2OD12Mj6xPFA3KM7:TR?= NHTDVGxUSU6JRWK=
MPP-89 NHfxWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jTemlEPTB;NEKuOVg4PSEQvF2= Mlj5V2FPT0WU
MV-4-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTR{LkmwOlch|ryP MX\TRW5ITVJ?
EoL-1- NFXiPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfzUHdsUUN3ME20OE4yPTZ6IN88US=> MmLxV2FPT0WU
CW-2 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnTTWM2OD12ND64N|QzKM7:TR?= MYnTRW5ITVJ?
HT M4PTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrvXVBKSzVyPUS1MlcxODdizszN M3;UUHNCVkeHUh?=
SW954 NV;FNGVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPwTWM2OD12Nz60NVI5KM7:TR?= MmTpV2FPT0WU
A3-KAW MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4cmlEPTB;NEmuPFA3OSEQvF2= MWfTRW5ITVJ?
TC-YIK MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVyLkCzOlMh|ryP NGTV[FJUSU6JRWK=
SW962 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTV2LkizOVch|ryP MV\TRW5ITVJ?
KP-N-RT-BM-1 NH3BTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqwfFZEUUN3ME21Ok43PjN6IN88US=> MWrTRW5ITVJ?
NCI-H1395 NWS0UYk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTV6LkixO|Ih|ryP MmTBV2FPT0WU
RPMI-8402 NGe3SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTV6Lkm1NlYh|ryP NF\2OnNUSU6JRWK=
SCH M3\jU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZyLkm2N|gh|ryP M3zuWHNCVkeHUh?=
NCI-H2196 NXHpNmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXoUWZKSzVyPU[xMlI{OSEQvF2= M4TJTXNCVkeHUh?=
LOXIMVI MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZzLkiyOlYh|ryP Ml7CV2FPT0WU
TGBC24TKB MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSfZhKSzVyPU[yMlE1QTFizszN NUTROYh[W0GQR1XS
SK-MEL-2 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHjSVl1UUN3ME22N{46QDl{IN88US=> M2DqRXNCVkeHUh?=
U-698-M MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fSU2lEPTB;NkiuOVY5PyEQvF2= M4\OXHNCVkeHUh?=
NCI-H1522 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\sN2lEPTB;NkmuNFA1PyEQvF2= M{LlXHNCVkeHUh?=
UACC-812 NW\sSGx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH1TWM2OD14OT61NlA6KM7:TR?= MXLTRW5ITVJ?
MHH-CALL-2 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTdyLkC2JO69VQ>? M4nTOXNCVkeHUh?=
NB5 M4LjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q2R2lEPTB;N{CuN|Q3QCEQvF2= MYPTRW5ITVJ?
KARPAS-299 M4HuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTdyLkS0OFch|ryP Mn;yV2FPT0WU
NCI-H1694 NIjZWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jaUmlEPTB;N{GuNFMzKM7:TR?= MWLTRW5ITVJ?
NCI-H82 NVnXU2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTdzLkm1NFch|ryP NUXPflhGW0GQR1XS
SCC-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HLR2lEPTB;N{KuN|Qh|ryP MnPIV2FPT0WU
NCI-H1436 NXy1fJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\QWVdbUUN3ME23Nk44PDV4IN88US=> MlS5V2FPT0WU
ATN-1 M{HW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LWXmlEPTB;N{SuOVA2KM7:TR?= M3[xO3NCVkeHUh?=
RPMI-8866 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTd2Lke1NFkh|ryP MnHlV2FPT0WU
HCC1599 NYXXUlgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTd2Lki3N|Ih|ryP M3S0W3NCVkeHUh?=
NCI-H1155 NUTqc2duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7aTYdzUUN3ME23OE46OzZ5IN88US=> M2THWnNCVkeHUh?=
DOHH-2 NFXZXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTd2Lkm1NVQh|ryP MnvlV2FPT0WU
SK-NEP-1 NWPsSYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDUXpVuUUN3ME23OU4xPzV2IN88US=> NWDESJo1W0GQR1XS
HCC1187 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHib3pKSzVyPUe3MlYyOjJizszN MnTUV2FPT0WU
NCI-H322M MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fJVGlEPTB;N{iuN|cxQSEQvF2= MXrTRW5ITVJ?
NCI-H526 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHjVWpKSzVyPUe4MlU5PzdizszN NWPpXpBiW0GQR1XS
NCI-H2171 NEXpblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK4TWM2OD15OT60NVM3KM7:TR?= MY\TRW5ITVJ?
COLO-668 NELHbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRThzLkW4PFQh|ryP MkTVV2FPT0WU
RS4-11 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTh{LkK1NFUh|ryP MlHLV2FPT0WU
NCI-H716 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXaTWM2OD16Mj65NFc2KM7:TR?= MnnHV2FPT0WU
LU-134-A NEi3NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\3TWM2OD16Mz6xN|UyKM7:TR?= M2DYWXNCVkeHUh?=
RPMI-8226 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTh2LkKxNFch|ryP NEDyWIlUSU6JRWK=
KY821 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X4VmlEPTB;OUGuOlU2OSEQvF2= NVPWeYVDW0GQR1XS
ECC4 NGTqbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL4TWM2OD17Mz64NlY6KM7:TR?= MVLTRW5ITVJ?
EW-3 M4C0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTl2LkmwPFEh|ryP NU\xXlBjW0GQR1XS
NB7 NFz5SpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTl3Lke3PFYh|ryP NFLPOYJUSU6JRWK=
NCI-H720 NHXHXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:zTWM2OD17OD60NFYyKM7:TR?= Mm[wV2FPT0WU
NCI-H446 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTl7Lke1PFgh|ryP NVrwb5htW0GQR1XS
NCI-H889 M3nSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{THcGlEPTB;MUC0MlI1OiEQvF2= MXPTRW5ITVJ?
EW-22 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFyNj6xPUDPxE1? M2X2XXNCVkeHUh?=
BV-173 NIPUbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnaXXZOUUN3ME2xNFgvPzJ6IN88US=> M2f6fnNCVkeHUh?=
WSU-NHL M3Lvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq4SXgzUUN3ME2xNFkvPjdzIN88US=> MU\TRW5ITVJ?
MN-60 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rTZWlEPTB;MUC5MlY6KM7:TR?= NF3BdpBUSU6JRWK=
DG-75 NVnKepBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHZSWt3UUN3ME2xNVMvOzV{IN88US=> NInOfVVUSU6JRWK=
DMS-79 NHr0OZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULuToNiUUN3ME2xNVcvOzh{IN88US=> MljyV2FPT0WU
SK-MEL-1 NV\LOIlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrReHJLUUN3ME2xNVgvODB7IN88US=> NYPsPG1qW0GQR1XS
DMS-153 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF{MT63OFUh|ryP Mki5V2FPT0WU
NCI-H510A NHfQeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF{Nz6zNkDPxE1? NFrUPHhUSU6JRWK=
BE-13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLYWmRKSzVyPUGzOE4xPDRizszN MYrTRW5ITVJ?
KP-N-YS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF|OT63N|Yh|ryP NEXQZY9USU6JRWK=
SUP-T1 NYCyWJZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH4fY1KSzVyPUG0N{44ODhizszN MlvFV2FPT0WU
EW-12 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjadJdyUUN3ME2xOFQvPjl7IN88US=> NGnRTWFUSU6JRWK=
NB14 M1;TRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF2Nz6wPFIh|ryP M1\TU3NCVkeHUh?=
MDA-MB-134-VI MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF2OD6yOlgh|ryP MWPTRW5ITVJ?
NCI-H1770 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ETWM2OD1zNU[uNlc6KM7:TR?= NF2zPYRUSU6JRWK=
TUR M{m2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnlTWM2OD1zNkeuPFch|ryP NYPkd|dWW0GQR1XS
NCI-H1417 NVntb3poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXwU21KSzVyPUG4NE4{OzFizszN MXXTRW5ITVJ?
IMR-5 NHzEdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF6MT61O|Eh|ryP NWfWUpB2W0GQR1XS
NCI-H226 NGPWcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7ZPFFVUUN3ME2xPFgvQDZ4IN88US=> NFfvb5VUSU6JRWK=
NCI-H187 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHnNINTUUN3ME2xPVAvODZ2IN88US=> NWjFcJNKW0GQR1XS
SF539 NVnLdoJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfwfllKSzVyPUG5Nk44OjhizszN NHOwc3FUSU6JRWK=
TALL-1 NI\VTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHGTGxmUUN3ME2xPVgvOzB2IN88US=> NYnjWHNWW0GQR1XS
TE-441-T M2\mS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHjTWM2OD1zOUmuO|M6KM7:TR?= Mk\ZV2FPT0WU
REH NETRSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHGTWM2OD1{M{[uOlI3KM7:TR?= MXXTRW5ITVJ?
MS-1 NH;xbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7LdJFpUUN3ME2yN|kvOTJzIN88US=> Mn3qV2FPT0WU
THP-1 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LNbGlEPTB;Mk[0Mlc{QCEQvF2= M2nTPXNCVkeHUh?=
NCI-H1838 NX[0bVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPYU|lsUUN3ME2yO|EvPDV4IN88US=> MUDTRW5ITVJ?
P30-OHK MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PI[2lEPTB;MkizMlg1PyEQvF2= MUPTRW5ITVJ?
C8166 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\Yb5BkUUN3ME2zOFUvOzN6IN88US=> NX25fpluW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products4

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID